Thursday, 18 Jan 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
02 Oct 2016 Social Prime Therapeutics shows Xeljanz discontinuations at 30% by 6mos & 44% at 1 yr. 10% use it before MTX/other DMARDs
29 Sep 2016 Social Humira and Xeljanz have equal outcomes in patient reported outcomes of efficacy in 12 mos ORAL study.
28 Sep 2016 Social Yale study of Alopecia (areata or universalis) showed 32% of 66pts improved with tofacitinib 5mg bid after 3 months.
27 Sep 2016 News Ilaris Gets FDA Approval for Rare Febrile Disorders
26 Sep 2016 News FDA Approves Stelara for Crohn's Colitis
23 Sep 2016 News Restricting High Price Drugs - A Dangerous Trend?
20 Sep 2016 Social JIA Uveitis refractory to MTX, DMARDs, TNFi, successfully Rx in 10/17 w/ Tocilizumab after 5.7 mos,7 steroid sparing
20 Sep 2016 News After the 1st TNF Inhibitor, a Non-TNF Biologic is Next Best
14 Sep 2016 Social RTX biosimilar CT-P10 comparable to rituximab in efficacy, pharmacodynamics, & immunogenicity/safety. @DrPetryna
14 Sep 2016 Social TNFi induced Psoriasis can be treated w/ TNFi D/C, another TNFi (48-85% recurrence) or Stelara. Good short review
07 Sep 2016 News Is Biologic Safety Different in the Elderly?
07 Sep 2016 Social EU grants approval for Orencia (abatacept; IV or SC) for MTX naive (early) RA patients with moderate-severe disease
07 Sep 2016 Social Power doppler synovitis correlates better w/ S100 Calprotectin levels(more than ESR CRP) & w/ low TNFi trough levels
06 Sep 2016 Social 30% of Biologics us is monotherapy. Choy etal reviews comparative success, reasons, pitfalls of biologic monotherapy
30 Aug 2016 Social Dr Carol Langford Gr Rounds - ANCA levels do NOT correlate well with disease activity and should not be used to guide therapy
25 Aug 2016 Social Ixekizumab (Taltz), IL-17 inhibitor, better than Placebo, but same as Humira @24wks in treating psoriatic arthritis
23 Aug 2016 Social Idiopathic Recurrent Pericarditis follows ~20% acute pericarditis; responds VERY well to IL-1 inhibition (anakinra)
10 Aug 2016 Social Abbvies IL-6 drug vobarilizumab (+MTX) failed to meet ACR20 primary endpoint against MTX alone (devloped w/ Ablynx)
09 Aug 2016 Social In Japan, persistence on biologics highest in biologic-naïve (>95%) and older Pts & lowest w/ more comorbidities.
05 Aug 2016 Social CVS pharmacy drops brand name drugs and prefers biosimilar agents for diabetes and cancer care.